GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (STU:DR6) » Definitions » 3-Year EPS without NRI Growth Rate

ACADIA Pharmaceuticals (STU:DR6) 3-Year EPS without NRI Growth Rate : 40.90% (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals 3-Year EPS without NRI Growth Rate?

ACADIA Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was €0.09.

During the past 3 years, the average EPS without NRI Growth Rate was 40.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 23.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of ACADIA Pharmaceuticals was 40.90% per year. The lowest was -74.60% per year. And the median was 8.80% per year.


Competitive Comparison of ACADIA Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, ACADIA Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



ACADIA Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


ACADIA Pharmaceuticals  (STU:DR6) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


ACADIA Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals (STU:DR6) Business Description

Industry
Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (STU:DR6) Headlines

No Headlines